On June 1, Baoji Pharma-B declined 5.46% in regular trading, trading at 23.06 HKD/share, with trading volume of approximately 43.34 million HKD. The stock continued to face selling pressure as the first trading day following its formal inclusion in the MSCI Global Index, which took effect after the May 29 close.

The broader biotechnology sector experienced systemic weakness on the same day, with BEIGENE down 3.56%, Innovent Bio down 3.0%, and SKB Bio down 7.1%, amplifying downward pressure on individual names. MSCI index inclusion events often trigger short-term sell-the-news dynamics as passive rebalancing flows complete.

Baoji Pharma-B has been trading at depressed levels since a 65% flash crash in late April that wiped approximately 58.5 billion HKD from its market capitalization. Despite recent positive developments — including the appointment of Dr. Liu Yanjun as new board chairman, a first-time Buy rating from Zhongyou Securities, and the controlling shareholder signaling intent to increase holdings — market confidence remains in an early-stage recovery phase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)